Article Text

Download PDFPDF

226 ‘Off-the-shelf’ CD19-CAR-T cells generated from umbilical cord blood display superior anti-tumor fitness and lower pro-inflammatory activity as compared to peripheral blood-derived engineered T cells
  1. Asma Al Sulaiti1,
  2. Mohammed El Anbari1,
  3. Mohammed Toufiq1,
  4. Shana Jacob1,
  5. Saroja Kotegar Balayya1,
  6. Salim Bougarn1,
  7. Evonne Chin-Smith1,
  8. Alex Issam Tout1,
  9. Neha Gopinath1,
  10. Damilola Olagunju1,
  11. Chiara Cugno1,
  12. Sara Deola1,
  13. Suruchi Mohan1,
  14. Damien Chaussabel1,
  15. Chiara Bonini2,
  16. Monica Casucci2 and
  17. Cristina Maccalli1
  1. 1Sidra Medicine, Doha, Qatar
  2. 2IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background The principal goal of this study is to generate ’off-the-shelf’ CD19-CAR-T cells utilizing umbilical cord blood (UCB) as source of T lymphocytes and characterize through multi-omics their phenotype and functional properties.

Methods T cells were isolated from UBCs (N=15) and, upon activation in vitro using CD3 and CD28 mAbs, transduced with lentiviral vectors encoding for CD19-CD28z-or CD19–4-1BBz-CARs. Engineered T cells were also produced from the peripheral blood lymphocytes (PBL; N=5) as reference. The multidimensional phenotype analysis was utilized to assess the differentiation and activation status of the T cells. CD19-CAR-T cells were co-incubated or not with either CD19+ or CD19- target cells to mimic the antigen-mediated engagement of the CARs, and then, multi-omics analyses, including metabolomics, transcriptomics, and in vitro functional assays, (Elispot, Luminex) were performed.

Results CD19-CAR T cells with early stage of differentiation (CD45RA+) co-expressing either ICOS or BTLA were observed in UCB- vs. PBL-CAR T cells (p<0.0002-<0.05). Distinct transcriptomic and functional profiles were also observed according to the source of T cells used for engineering and the method of activation of the cells. The transcriptomic profiling of these cells showed that chemokines (e.g., CCL1, CCL2, CCL5), CD38 and CD69 molecules, involved in chemotaxis, adhesion and activation, were up-regulated in UCB- vs. PBC-CD19-CAR-T cells (p<0.001). Similar pattern was observed for IFN signaling molecules and IL-2Rγ chain. Other molecules mediating pro-inflammatory functions, such as IL-3, IL-26, Il-27, TLR2 and 5, were overexpressed in PBMC-CD19-CAR-T cells (p<0.001). Differential MicroRNA (miRNAs) patters were also identified. The multiplex analyses of the antigen-specific release of cytokines, chemokines and growth factors, highlighted superior levels of TH1-associated cytokines or cytotoxic molecules (p<0.05), and no or lower levels of pro-inflammatory molecules (e.g., CD40L, IL-1β, IL-3, IL-10, IL-15) by UCB- vs. PBMC-CAR-T cells. Differential antigen-specific metabolomic signatures were also found in association with the source of T lymphocytes expressing the CD19-CARs.

Conclusions Although the integration of the obtained multi-omics data sets is still ongoing, the deep molecular profiling of ‘off-the-shelf’ CD19-CAR-T cells allowed to assess that UCB-derived T cells are endowed with superior anti-tumor ‘fitness’ and lower risk of inducing in vivo cytokine release syndrome.

Ethics Approval The study obtained ethics approval of the Sidra Medicine institutional review board(s), ID#1500788b and all the participants gave informed consent before taking part.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.